MDSpire - Summary
FDA & Government News

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

Share

An investigational Lyme disease vaccine candidate, PF-07307405, has shown over 70% efficacy in a phase 3 clinical trial, with a 73% reduction in confirmed Lyme disease cases after four doses. Conducted in high-incidence areas across the U.S., Canada, and Europe, the trial involved participants aged 5 and older, revealing the vaccine's potential to inhibit Borrelia burgdorferi's migration from ticks to humans. Despite not meeting pre-specified primary statistical criteria, results indicate clinically meaningful efficacy and patient safety.

Original Source(s)

Lyme Vaccine Advances in Late Trial

  • by Kathryn Wighton

  • March 23, 2026

Related Content

Can Shorter TB Prevention Regimens Work?

Randomized study evaluates efficacy, safety, and completion in high-risk patients

Why Copilots Failed in R&D and What Comes Next 

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.